Previous Article | Next Article 
Molecular and Cellular Biology, February 2000, p. 947-956, Vol. 20, No. 3
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Complex Effects of Naturally Occurring Mutations in
the JAK3 Pseudokinase Domain: Evidence for Interactions between the
Kinase and Pseudokinase Domains
Min
Chen,1,*
Alan
Cheng,2
Fabio
Candotti,3
Yong-Jie
Zhou,1
Anka
Hymel,1
Anders
Fasth,4
Luigi D.
Notarangelo,5 and
John
J.
O'Shea1
Lymphocyte Cell Biology Section, Arthritis
and Rheumatism Branch, National Institute of Arthritis, Musculoskeletal
and Skin Diseases,1 Howard Hughes
Medical Institute
National Institutes of Health Research Scholars
Program,2 Clinical Gene Therapy Branch,
National Human Genome Research Institute,3
National Institutes of Health, Bethesda, Maryland 20892;
Department of Pediatrics, University of Goteborg, SE-41685
Goteborg, Sweden4; and Department of
Pediatrics, University of Brescia, I-25123 Brescia,
Italy5
Received 5 October 1999/Accepted 5 November 1999
The structure of Janus kinases (JAKs) is unique among protein
tyrosine kinases in having tandem, nonidentical kinase and pseudokinase domains. Despite its conservation in evolution, however, the function of the pseudokinase domain remains poorly understood. Lack of JAK3
expression results in severe combined immunodeficiency (SCID). In this
study, we analyze two SCID patients with mutations in the JAK3
pseudokinase domain, which allows for protein expression but disrupts
the regulation of the kinase activity. Specifically, these mutant forms
of JAK3 had undetectable kinase activity in vitro but were
hyperphosphorylated both in patients' Epstein-Barr virus-transformed B
cells and when overexpressed in COS7 cells. Moreover, reconstitution of
cells with these mutants demonstrated that, although they were
constitutively phosphorylated basally, they were unable to transmit
cytokine-dependent signals. Further analysis showed that the isolated
catalytic domain of JAK3 was functional whereas either the addition of
the pseudokinase domain or its deletion from the full-length molecule
reduced catalytic activity. Through coimmunoprecipitation of the
isolated pseudokinase domain with the isolated catalytic domain, we
provide the first evidence that these two domains interact.
Furthermore, whereas the wild-type pseudokinase domain modestly
inhibited kinase domain-mediated STAT5 phosphorylation, the
patient-derived mutants markedly inhibited this phosphorylation. We
thus conclude that the JAK3 pseudokinase domain is essential for JAK3
function by regulating its catalytic activity and autophosphorylation.
We propose a model in which this occurs via intramolecular interaction
with the kinase domain and that increased inhibition of kinase activity
by the pseudokinase domain likely contributes to the disease
pathogenesis in these two patients.
*
Corresponding author. Mailing address:
LCBS/ARB/NIAMS/NIH, 10/9N262, 10 Center Dr., MSC-1820, Bethesda,
MD 20892. Phone: (301) 496-2541. Fax: (301) 402-0012. E-mail:
chenm{at}arb.niams.nih.gov.
Molecular and Cellular Biology, February 2000, p. 947-956, Vol. 20, No. 3
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kleinhofs, A., Brueggeman, R., Nirmala, J., Zhang, L., Mirlohi, A., Druka, A., Rostoks, N., Steffenson, B. J.
(2009). Barley Stem Rust Resistance Genes: Structure and Function. The Plant Genome
2: 109-120
[Abstract]
[Full Text]
-
Gakovic, M., Ragimbeau, J., Francois, V., Constantinescu, S. N., Pellegrini, S.
(2008). The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor. J. Biol. Chem.
283: 18522-18529
[Abstract]
[Full Text]
-
Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., Martinelli, S., Fragale, A., Sanchez, M., Tavolaro, S., Messina, M., Cazzaniga, G., Camera, A., Pizzolo, G., Tornesello, A., Vignetti, M., Battistini, A., Cave, H., Gelb, B. D., Renauld, J.-C., Biondi, A., Constantinescu, S. N., Foa, R., Tartaglia, M.
(2008). Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. JEM
205: 751-758
[Abstract]
[Full Text]
-
Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P. C., Behrmann, I., Haan, C.
(2008). Dual Role of the Jak1 FERM and Kinase Domains in Cytokine Receptor Binding and in Stimulation-Dependent Jak Activation. J. Immunol.
180: 998-1007
[Abstract]
[Full Text]
-
Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F., Rossjohn, J.
(2006). The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood
107: 176-183
[Abstract]
[Full Text]
-
Staerk, J., Kallin, A., Demoulin, J.-B., Vainchenker, W., Constantinescu, S. N.
(2005). JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation: CROSS-TALK WITH IGF1 RECEPTOR. J. Biol. Chem.
280: 41893-41899
[Abstract]
[Full Text]
-
Pesu, M., O'Shea, J., Hennighausen, L., Silvennoinen, O.
(2005). Identification of an Acquired Mutation in Jak2 Provides Molecular Insights into the Pathogenesis of Myeloproliferative Disorders. Mol. Interv.
5: 211-215
[Abstract]
[Full Text]
-
Hofmann, S. R., Lam, A. Q., Frank, S., Zhou, Y.-J., Ramos, H. L., Kanno, Y., Agnello, D., Youle, R. J., O'Shea, J. J.
(2004). Jak3-Independent Trafficking of the Common {gamma} Chain Receptor Subunit: Chaperone Function of Jaks Revisited. Mol. Cell. Biol.
24: 5039-5049
[Abstract]
[Full Text]
-
Roberts, J. L., Lengi, A., Brown, S. M., Chen, M., Zhou, Y.-J., O'Shea, J. J., Buckley, R. H.
(2004). Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood
103: 2009-2018
[Abstract]
[Full Text]
-
Shaw, M. H., Boyartchuk, V., Wong, S., Karaghiosoff, M., Ragimbeau, J., Pellegrini, S., Muller, M., Dietrich, W. F., Yap, G. S.
(2003). A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA
100: 11594-11599
[Abstract]
[Full Text]
-
Aringer, M., Hofmann, S. R., Frucht, D. M., Chen, M., Centola, M., Morinobu, A., Visconti, R., Kastner, D. L., Smolen, J. S., O'Shea, J. J.
(2003). Characterization and Analysis of the Proximal Janus Kinase 3 Promoter. J. Immunol.
170: 6057-6064
[Abstract]
[Full Text]
-
Saharinen, P., Vihinen, M., Silvennoinen, O.
(2003). Autoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain. Mol. Biol. Cell
14: 1448-1459
[Abstract]
[Full Text]
-
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., Sudarsanam, S.
(2002). The Protein Kinase Complement of the Human Genome. Science
298: 1912-1934
[Abstract]
[Full Text]
-
Saharinen, P., Silvennoinen, O.
(2002). The Pseudokinase Domain Is Required for Suppression of Basal Activity of Jak2 and Jak3 Tyrosine Kinases and for Cytokine-inducible Activation of Signal Transduction. J. Biol. Chem.
277: 47954-47963
[Abstract]
[Full Text]
-
Lindauer, K., Loerting, T., Liedl, K. R., Kroemer, R. T.
(2001). Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng Des Sel
14: 27-37
[Abstract]
[Full Text]
-
O'Shea, J. J, Visconti, R., Cheng, T. P, Gadina, M.
(2000). Jaks and Stats as therapeutic targets. Ann Rheum Dis
59: i115-118
[Abstract]
[Full Text]
-
Yeh, T. C., Dondi, E., Uzé, G., Pellegrini, S.
(2000). A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc. Natl. Acad. Sci. USA
10.1073/pnas.160130297v1
[Abstract]
[Full Text]
-
Yeh, T. C., Dondi, E., Uze, G., Pellegrini, S.
(2000). A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. Proc. Natl. Acad. Sci. USA
97: 8991-8996
[Abstract]
[Full Text]